BRN
☆    

Turkey,
2015-07-15 12:21
(3180 d 01:30 ago)

(edited by BRN on 2015-07-15 16:44)
Posting: # 15086
Views: 5,306
 

 Fixed dose com­bi­na­tion and single administration analysis [General Sta­tis­tics]

Dear All,

We have a BE study for a fixed dose combination (FDC) product (T) which does not have an original reference. So our reference product (R) becomes administration of R1 and R2 in combination (R=R1+R2). However in other periods these original products are administered as monotherapy as per local regulations.

The protocol mentions the BE conclusion will be based on T vs. R.

Now my question is, what's the best approach for the statistical analysis?
  1. Treat the study as 2 period with T vs. R and code accordingly:
    (Treatments= T, R; Periods= 1, 2; Sequence= TR, RT).

  2. Treat the study as 3 period with T vs. R and R1 since R2 will not have one of the active ingredients, and code accordingly:
    (Treatments=T, R, R1; Periods: 1, 2, 3; Sequence:TRR1, TR1R, R1RT)

  3. Treat the study as 4 period with T vs. R, R1, and R2, and code accordingly:
    (Treatments=T, R, R1, R2; Periods: 1, 2, 3, 4; Sequence:TRR1R2, RR1TR2, ....)

From my point of view the best approach will be the first option but I'd like to hear some expert comments. Is there any other options, suggestions?

Thank you in advance for your kind support.

Regards,
BRN
jag009
★★★

NJ,
2015-07-16 08:22
(3179 d 05:29 ago)

@ BRN
Posting: # 15090
Views: 4,293
 

 Fixed dose combination and single administration analysis

Hi,

I don't understand your reasons for #2 and #3.

You said the test is a FDC and there is no reference FDC. Therefore your reference would be to administer 2 products (R1 and R2).. #1 will work. I ran this kind of study for an NDA FDC before and there were no issues.

Thanks
John
BRN
☆    

Turkey,
2015-07-16 13:23
(3179 d 00:27 ago)

@ jag009
Posting: # 15094
Views: 4,231
 

 Fixed dose combination and single administration analysis

Hi John, thank you for your reply.

❝ I don't understand your reasons for #2 and #3.


Actually the study is a 4 period study. The aim is to compare T and R in terms of BE, additionally to investigate drug interactions at the same time since there is no FDC as reference. That's why investigating the BE as 2 period study makes sence to me as well, however I've seen examples such as #2 and #3, that's why trying to make sure which is the best approach.

Regards,
BRN
Dr_Dan
★★  

Germany,
2015-07-16 11:12
(3179 d 02:39 ago)

@ BRN
Posting: # 15092
Views: 4,264
 

 Fixed dose combination and single administration analysis

Dear BRN,
As you explained you have a fixed dose combination (FDC) product which does not have an original reference. So bioequivalence with the reference products R1 and R2 in combination (R=R1+R2) is only one aspect. The other question you Need to answer is: How do you know that this combination is reasonable from a PK point of view? Therefore you have to conduct additionally a drug-drug-interaction (DDI)study.
BE: single dose 2x2 design T vs. R1+R2
DDI: multiple dose R1, R2, R1+R2
I hope this helps.
Kind regards
Dr_Dan

Kind regards and have a nice day
Dr_Dan
UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
102 visitors (0 registered, 102 guests [including 6 identified bots]).
Forum time: 12:51 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5